MedWatch

Zealand announces positive results with glucagon analogue

This week, the Danish biotech company Zealand Pharma obtained positive results with a glucagon analogue, dasiglucagon, to be used in a dual-hormone artificial pancreas from a US-based medtech company. Results from a second trial on the use of dasiglucagon in the artificial pancreas system are expected at the end of June 2017.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

MedWatch-indeks: Endnu en tung uge for biotekaktierne

Nedturen ser ud til at fortsætte for de danske biotekaktier, som alle oplevede kursfald i uge 47. Novo Nordisk ender for en efterhånden sjælden gangs skyld på toppen i MedWatch-indekset, efter at have givet markedet tiltro til fremtiden på sin kapitalmarkedsdag.

Latest Top picks in English

Related articles